Trial Profile
Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients
Status:
Suspended
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Biomarker
- 12 May 2016 Planned End Date changed from 1 Mar 2016 to 1 Aug 2016.
- 12 May 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Aug 2016.
- 30 Mar 2016 Planned number of patients changed from 100 to 50 as per ClinicalTrials.gov record.